Methadone disposition in oral fluid during pharmacotherapy for opioid-dependence

Teresa R. Gray, Riet Dams, Robin E. Choo, Hendree E. Jones, Marilyn A. Huestis

Research output: Contribution to journalArticle

Abstract

Introduction: Oral fluid testing is widely used for detecting drug exposure, but data describing methadone and metabolites in oral fluid during pharmacotherapy for opioid-dependence are relatively limited. Methods: 414 oral fluid specimens from 16 opioid-dependent pregnant women receiving daily methadone were analyzed for methadone, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP), and methadol by liquid chromatography-mass spectrometry. Results: All oral fluid specimens contained methadone greater than 1. ng/mL; 88% were positive for EDDP and 12% for methadol. Over 95% of oral fluid specimens exceeded the 20. ng/mL methadone cutoff set by the European Driving Under the Influence of Drugs, Alcohol and Medicines (DRUID) study. Methadone and EDDP oral fluid concentrations were highly variable within and between participants, did not predict methadone dose, but were negatively correlated with pH. Conclusion: Methadone was readily identified in oral fluid at concentrations greater than 20. ng/mL following daily 30-110. mg/day methadone pharmacotherapy. As no specimens contained only EDDP or methadol, there was no advantage to including these analytes for identification of methadone exposure. As nearly all oral fluid specimens from methadone-maintained patients exceeded the DRUID guideline, the 20. ng/mL cutoff appears to be sensitive enough to detect daily methadone exposure; however, additional indicators of behavioral and/or motor impairment would be necessary to provide evidence of driving impairment.

Original languageEnglish (US)
Pages (from-to)98-102
Number of pages5
JournalForensic Science International
Volume206
Issue number1-3
DOIs
StatePublished - Mar 20 2011

Fingerprint

Methadone
Opioid Analgesics
Drug Therapy
Methadyl Acetate
Liquid Chromatography
Pharmaceutical Preparations
Pregnant Women
Mass Spectrometry
Alcohols
Guidelines

Keywords

  • Methadone
  • Opioid-dependence
  • Oral fluid
  • Saliva

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Methadone disposition in oral fluid during pharmacotherapy for opioid-dependence. / Gray, Teresa R.; Dams, Riet; Choo, Robin E.; Jones, Hendree E.; Huestis, Marilyn A.

In: Forensic Science International, Vol. 206, No. 1-3, 20.03.2011, p. 98-102.

Research output: Contribution to journalArticle

Gray, Teresa R. ; Dams, Riet ; Choo, Robin E. ; Jones, Hendree E. ; Huestis, Marilyn A. / Methadone disposition in oral fluid during pharmacotherapy for opioid-dependence. In: Forensic Science International. 2011 ; Vol. 206, No. 1-3. pp. 98-102.
@article{3b074e3c469048d9bb7b9e1c9d07388f,
title = "Methadone disposition in oral fluid during pharmacotherapy for opioid-dependence",
abstract = "Introduction: Oral fluid testing is widely used for detecting drug exposure, but data describing methadone and metabolites in oral fluid during pharmacotherapy for opioid-dependence are relatively limited. Methods: 414 oral fluid specimens from 16 opioid-dependent pregnant women receiving daily methadone were analyzed for methadone, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP), and methadol by liquid chromatography-mass spectrometry. Results: All oral fluid specimens contained methadone greater than 1. ng/mL; 88{\%} were positive for EDDP and 12{\%} for methadol. Over 95{\%} of oral fluid specimens exceeded the 20. ng/mL methadone cutoff set by the European Driving Under the Influence of Drugs, Alcohol and Medicines (DRUID) study. Methadone and EDDP oral fluid concentrations were highly variable within and between participants, did not predict methadone dose, but were negatively correlated with pH. Conclusion: Methadone was readily identified in oral fluid at concentrations greater than 20. ng/mL following daily 30-110. mg/day methadone pharmacotherapy. As no specimens contained only EDDP or methadol, there was no advantage to including these analytes for identification of methadone exposure. As nearly all oral fluid specimens from methadone-maintained patients exceeded the DRUID guideline, the 20. ng/mL cutoff appears to be sensitive enough to detect daily methadone exposure; however, additional indicators of behavioral and/or motor impairment would be necessary to provide evidence of driving impairment.",
keywords = "Methadone, Opioid-dependence, Oral fluid, Saliva",
author = "Gray, {Teresa R.} and Riet Dams and Choo, {Robin E.} and Jones, {Hendree E.} and Huestis, {Marilyn A.}",
year = "2011",
month = "3",
day = "20",
doi = "10.1016/j.forsciint.2010.06.031",
language = "English (US)",
volume = "206",
pages = "98--102",
journal = "Forensic Science International",
issn = "0379-0738",
publisher = "Elsevier Ireland Ltd",
number = "1-3",

}

TY - JOUR

T1 - Methadone disposition in oral fluid during pharmacotherapy for opioid-dependence

AU - Gray, Teresa R.

AU - Dams, Riet

AU - Choo, Robin E.

AU - Jones, Hendree E.

AU - Huestis, Marilyn A.

PY - 2011/3/20

Y1 - 2011/3/20

N2 - Introduction: Oral fluid testing is widely used for detecting drug exposure, but data describing methadone and metabolites in oral fluid during pharmacotherapy for opioid-dependence are relatively limited. Methods: 414 oral fluid specimens from 16 opioid-dependent pregnant women receiving daily methadone were analyzed for methadone, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP), and methadol by liquid chromatography-mass spectrometry. Results: All oral fluid specimens contained methadone greater than 1. ng/mL; 88% were positive for EDDP and 12% for methadol. Over 95% of oral fluid specimens exceeded the 20. ng/mL methadone cutoff set by the European Driving Under the Influence of Drugs, Alcohol and Medicines (DRUID) study. Methadone and EDDP oral fluid concentrations were highly variable within and between participants, did not predict methadone dose, but were negatively correlated with pH. Conclusion: Methadone was readily identified in oral fluid at concentrations greater than 20. ng/mL following daily 30-110. mg/day methadone pharmacotherapy. As no specimens contained only EDDP or methadol, there was no advantage to including these analytes for identification of methadone exposure. As nearly all oral fluid specimens from methadone-maintained patients exceeded the DRUID guideline, the 20. ng/mL cutoff appears to be sensitive enough to detect daily methadone exposure; however, additional indicators of behavioral and/or motor impairment would be necessary to provide evidence of driving impairment.

AB - Introduction: Oral fluid testing is widely used for detecting drug exposure, but data describing methadone and metabolites in oral fluid during pharmacotherapy for opioid-dependence are relatively limited. Methods: 414 oral fluid specimens from 16 opioid-dependent pregnant women receiving daily methadone were analyzed for methadone, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP), and methadol by liquid chromatography-mass spectrometry. Results: All oral fluid specimens contained methadone greater than 1. ng/mL; 88% were positive for EDDP and 12% for methadol. Over 95% of oral fluid specimens exceeded the 20. ng/mL methadone cutoff set by the European Driving Under the Influence of Drugs, Alcohol and Medicines (DRUID) study. Methadone and EDDP oral fluid concentrations were highly variable within and between participants, did not predict methadone dose, but were negatively correlated with pH. Conclusion: Methadone was readily identified in oral fluid at concentrations greater than 20. ng/mL following daily 30-110. mg/day methadone pharmacotherapy. As no specimens contained only EDDP or methadol, there was no advantage to including these analytes for identification of methadone exposure. As nearly all oral fluid specimens from methadone-maintained patients exceeded the DRUID guideline, the 20. ng/mL cutoff appears to be sensitive enough to detect daily methadone exposure; however, additional indicators of behavioral and/or motor impairment would be necessary to provide evidence of driving impairment.

KW - Methadone

KW - Opioid-dependence

KW - Oral fluid

KW - Saliva

UR - http://www.scopus.com/inward/record.url?scp=79952453403&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952453403&partnerID=8YFLogxK

U2 - 10.1016/j.forsciint.2010.06.031

DO - 10.1016/j.forsciint.2010.06.031

M3 - Article

C2 - 20667673

AN - SCOPUS:79952453403

VL - 206

SP - 98

EP - 102

JO - Forensic Science International

JF - Forensic Science International

SN - 0379-0738

IS - 1-3

ER -